Home Cart 0 Sign in  

[ CAS No. 1014-25-1 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 1014-25-1
Chemical Structure| 1014-25-1
Structure of 1014-25-1 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1014-25-1 ]

Related Doc. of [ 1014-25-1 ]

Alternatived Products of [ 1014-25-1 ]

Product Details of [ 1014-25-1 ]

CAS No. :1014-25-1 MDL No. :MFCD00813220
Formula : C9H9N3OS Boiling Point : -
Linear Structure Formula :- InChI Key :UJBCFMCQLVRXBQ-UHFFFAOYSA-N
M.W : 207.25 Pubchem ID :692882
Synonyms :

Calculated chemistry of [ 1014-25-1 ]

Physicochemical Properties

Num. heavy atoms : 14
Num. arom. heavy atoms : 11
Fraction Csp3 : 0.11
Num. rotatable bonds : 2
Num. H-bond acceptors : 3.0
Num. H-bond donors : 1.0
Molar Refractivity : 56.24
TPSA : 89.27 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.39 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.84
Log Po/w (XLOGP3) : 1.65
Log Po/w (WLOGP) : 1.8
Log Po/w (MLOGP) : 0.94
Log Po/w (SILICOS-IT) : 2.41
Consensus Log Po/w : 1.73

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.61
Solubility : 0.504 mg/ml ; 0.00243 mol/l
Class : Soluble
Log S (Ali) : -3.14
Solubility : 0.151 mg/ml ; 0.000728 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.21
Solubility : 0.127 mg/ml ; 0.000611 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.46

Safety of [ 1014-25-1 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1014-25-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1014-25-1 ]
  • Downstream synthetic route of [ 1014-25-1 ]

[ 1014-25-1 ] Synthesis Path-Upstream   1~18

  • 1
  • [ 79-19-6 ]
  • [ 100-09-4 ]
  • [ 1014-25-1 ]
YieldReaction ConditionsOperation in experiment
86.4% at 80℃; for 2.5 h; General procedure: A stirring mixture of benzoic acid (0.2442 g, 2.0 mmol), thiosemicarbazide (0.1823 g, 2.0 mmol) and POCl3 (1.2 ml) was heated at 80 oC for 2.5 h. After cooling down to room temperature, water (2.5 mL) was added. The reaction mixture was refluxed for 4 h. After cooling, the mixture was basified to pH 8 by the dropwise addition of 40percent NaOH solution under stirring. The precipitate was filtered and recrystallized from ethanol to yield 0.3130 g of the target compound 1a as a white solid ,Yield: 88.3percent.
82%
Stage #1: at 75℃; for 0.5 h;
Stage #2: for 4 h; Reflux
General procedure: 5.1.1
5-(4-Morpholinophenyl)-1,3,4-thiadiazol-2-amine (59)
A mixture of 4-morpholinobenzoic acid (5.18 g, 25 mmol) and N-aminothiourea (2.28 g, 25 mmol) in POCl3 (7 ml) was stirred vigorously at 75 °C for 0.5 h.
After addition of H2O (30 ml), the reaction mixture was heated under reflux for 4 h and basified to pH 8 by 50percent NaOH solution.
The mixture was filtered and the filter cake was recrystallized from ethanol to yield 3.90 g of compound 59 as a yellow crystal. Yield: 59percent; The synthetic procedures of compounds 60–81 were the same as that described above. 5.1.1.2
5-(4-Methoxyphenyl)-1,3,4-thiadiazol-2-amine (61)
Yield: 82percent, mp: 219-220 °C (EtOH). ESI-MS m/z: 208.2 [M+H]+; 1H NMR (DMSO-d6) δ 3.80 (s, 3H), 7.01-7.03 (m, 2H), 7.23 (s, 2H), 7.67-7.69 (m, 2H).
81.3% at 75℃; for 0.5 h; General procedure: A stirring mixture of benzoic acid (7.32 g, 60 mmol), N-aminothiourea(6.38 g, 70 mmol) and POCl3 (20 ml) washeated at 75 °C for 0.5 h. After cooling down to room temperature,water was added. The reaction mixture was refluxedfor 4 h. After cooling, the mixture was basified to pH8 by the drop-wise addition of 50percent NaOH solution understirring. The precipitate was filtered and re-crystallized from ethanol
76.09% at 85℃; for 10 h; p-Anisic acid (3.04 g, 20 mmol) and thiosemicarbazide (1.82 g,20 mmol) were dissolved in 30 mL of phosphorus oxychloride, thereaction mixture was refluxed at 85 °C for 10 h. After the reactionfinished, the mixture was poured into ice water slowly and thensaturate NaOH solution was added to adjust the pH value to 8.0under vigorous stirring. The mixture was extracted with ethyl acetatethree times, the organic layer was washed with brine anddried over anhydrous sodium sulfate. After solvent evaporation, thecrude product was purified by recrystallization from anhydrousethanol to get 3.15 g white powder, yield: 76.09percent. Melting point:188.1-189.5 °C. FT-IR (KBr, Disc, cm1): 3409.28 (m, ν NH2), 3377.72(m,ν NH2), 3304.97 (w), 3105.35 (m), 1647.15 (m), 1608.48 (m, ν CN),1578.80 (w), 1511.49 (s, ν benzene), 1465.51(s), 1304.97 (w), 1267.34(w), 1246.65 (s, ν OCH3), 1174.54 (m, ν OCH3), 1128.97 (w), 1052.67 (w),1031.98 (m), 978.88 (w), 829.22 (m), 658.86 (w), 520.48 (w). 1HNMR (DMSO-d6, 400 MHz, ppm) δ: 7.69-7.67 (d, J= 8.0 Hz, 2H),7.28 (s, 2H, NH2), 7.03-7.01 (d, J =8.0 Hz, 2H), 3.80 (s, 3H, OCH3). 13CNMR (100 MHz, DMSO) δ 167.85, 160.24, 156.25, 127.77, 123.61,144.46, 55.27. MS (ESI) m/z: found, [M+H]+, 208.0542; molecularformula C9H9N3OS requires [M+H]+, 208.0544.
65%
Stage #1: for 5 h; Reflux
Stage #2: for 7 h; Cooling; Reflux
General procedure: A mixture ofappropriate 4-n-alkoxybenzoic acid (10 mmol) and (0.91 g, 10 mmol) of thiosemicarbazidewith 5 mL of phosphorus oxychloride was refluxed gently for 5 hr. After cooling 50 mL of water was added, the mixture was then refluxed for 7 hr and filtered, neutralizedwith potassium hydroxide. The precipitate was washed with water and recrystallized fromethanol-water to give titled compound [III]n.

Reference: [1] Bioorganic and Medicinal Chemistry, 2008, vol. 16, # 14, p. 6663 - 6668
[2] Tetrahedron, 2018, vol. 74, # 31, p. 4161 - 4167
[3] Bioorganic and Medicinal Chemistry, 2014, vol. 22, # 21, p. 5766 - 5775
[4] Medicinal Chemistry, 2014, vol. 10, # 4, p. 376 - 381
[5] Medicinal Chemistry Research, 2012, vol. 21, # 6, p. 816 - 824
[6] Bulletin of the Korean Chemical Society, 2010, vol. 31, # 8, p. 2345 - 2350
[7] Bulletin of the Korean Chemical Society, 2011, vol. 32, # 3, p. 1011 - 1016
[8] Dyes and Pigments, 2017, vol. 145, p. 152 - 159
[9] Asian Journal of Chemistry, 2010, vol. 22, # 7, p. 5289 - 5296
[10] Journal of Chemical Research, 2014, vol. 38, # 6, p. 347 - 350
[11] Molecular Crystals and Liquid Crystals, 2014, vol. 593, # 1, p. 34 - 42
[12] Bulletin of the Chemical Society of Japan, 1982, vol. 55, # 2, p. 637 - 638
[13] Heterocyclic Communications, 2007, vol. 13, # 6, p. 387 - 392
[14] European Journal of Medicinal Chemistry, 2009, vol. 44, # 7, p. 2782 - 2786
[15] Journal of Chemical Research, 2009, # 11, p. 674 - 676
[16] Journal of Chemical Research, 2009, # 11, p. 671 - 673
[17] Chinese Chemical Letters, 2010, vol. 21, # 3, p. 301 - 304
[18] Journal of Chemical Research, 2010, vol. 34, # 12, p. 719 - 721
[19] Synthetic Communications, 2011, vol. 41, # 6, p. 864 - 870
[20] Journal of Chemical Research, 2011, vol. 35, # 8, p. 442 - 443
[21] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 3, p. 1181 - 1187
[22] Oriental Journal of Chemistry, 2011, vol. 27, # 2, p. 373 - 383
[23] Bioorganic and Medicinal Chemistry, 2012, vol. 20, # 9, p. 2789 - 2795
[24] Asian Journal of Chemistry, 2012, vol. 24, # 6, p. 2739 - 2743
[25] Journal of Chemical Research, 2012, vol. 36, # 4, p. 218 - 221
[26] European Journal of Medicinal Chemistry, 2012, vol. 56, p. 56 - 69,14
[27] Indian Journal of Heterocyclic Chemistry, 2011, vol. 20, # 4, p. 403 - 404
[28] RSC Advances, 2014, vol. 4, # 99, p. 55827 - 55831
[29] Letters in Drug Design and Discovery, 2015, vol. 12, # 4, p. 314 - 318
[30] RSC Advances, 2014, vol. 4, # 27, p. 14248 - 14253
[31] Chemical and Pharmaceutical Bulletin, 2014, vol. 62, # 6, p. 524 - 527
[32] Oriental Journal of Chemistry, 2015, vol. 31, # 4, p. 1873 - 1885
[33] Pharmazie, 2018, vol. 73, # 3, p. 123 - 127
[34] Bioorganic Chemistry, 2018, vol. 81, p. 88 - 92
[35] Molecules, 2018, vol. 23, # 10,
  • 2
  • [ 4334-74-1 ]
  • [ 1014-25-1 ]
Reference: [1] Monatshefte fur Chemie, 2013, vol. 144, # 5, p. 681 - 686
[2] Journal of Heterocyclic Chemistry, 2017, vol. 54, # 3, p. 1872 - 1879
[3] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 19, p. 5735 - 5738
[4] European Journal of Medicinal Chemistry, 2008, vol. 43, # 1, p. 135 - 141
[5] Liebigs Annalen der Chemie, 1994, # 10, p. 989 - 992
[6] Journal of the American Chemical Society, 1951, vol. 73, p. 906,908
[7] Journal of the Chemical Society, 1949, p. 1163,1167[8] Journal of the Chemical Society, 1950, p. 1579,1581
[9] Indian Journal of Chemistry, 1970, vol. 8, p. 509 - 513
[10] European Journal of Medicinal Chemistry, 2008, vol. 43, # 9, p. 1945 - 1954
[11] Medicinal Chemistry Research, 2008, vol. 17, # 2-7, p. 169 - 181
[12] Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, vol. 29, # 5, p. 611 - 618
[13] Journal of Organic Chemistry, 2015, vol. 80, # 2, p. 1018 - 1024
[14] Medicinal Chemistry Research, 2016, vol. 25, # 6, p. 1193 - 1203
[15] Catalysis Letters, 2018, vol. 148, # 11, p. 3486 - 3491
  • 3
  • [ 2290-65-5 ]
  • [ 3290-99-1 ]
  • [ 1014-25-1 ]
Reference: [1] RSC Advances, 2013, vol. 3, # 19, p. 6813 - 6816
  • 4
  • [ 833-84-1 ]
  • [ 1014-25-1 ]
Reference: [1] Asian Journal of Chemistry, 2011, vol. 23, # 3, p. 1305 - 1308
  • 5
  • [ 833-84-1 ]
  • [ 1014-25-1 ]
Reference: [1] Asian Journal of Chemistry, 2010, vol. 22, # 9, p. 6829 - 6839
[2] Journal of the Chemical Society, 1949, p. 1163,1167[3] Journal of the Chemical Society, 1950, p. 1579,1581
[4] Journal of the Indian Chemical Society, 1964, vol. 41, p. 295 - 298
[5] Arkivoc, 2017, vol. 2017, # 5, p. 293 - 300
  • 6
  • [ 79-19-6 ]
  • [ 874-90-8 ]
  • [ 1014-25-1 ]
Reference: [1] Russian Chemical Bulletin, 1995, vol. 44, # 10, p. 1955 - 1956[2] Izvestiya Akademi Nauk, Seriya Khimicheskaya, 1995, # 10, p. 2035 - 2036
  • 7
  • [ 123-11-5 ]
  • [ 1014-25-1 ]
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 19, p. 5735 - 5738
[2] Asian Journal of Chemistry, 2011, vol. 23, # 3, p. 1305 - 1308
[3] Letters in Drug Design and Discovery, 2012, vol. 9, # 7, p. 668 - 675
[4] Archiv der Pharmazie, 2013, vol. 346, # 11, p. 819 - 831
[5] Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, vol. 29, # 5, p. 611 - 618
[6] Journal of Organic Chemistry, 2015, vol. 80, # 2, p. 1018 - 1024
[7] Journal of Heterocyclic Chemistry, 2017, vol. 54, # 3, p. 1872 - 1879
[8] Catalysis Letters, 2018, vol. 148, # 11, p. 3486 - 3491
  • 8
  • [ 4334-74-1 ]
  • [ 1014-25-1 ]
Reference: [1] Archiv der Pharmazie, 2013, vol. 346, # 11, p. 819 - 831
  • 9
  • [ 54998-29-7 ]
  • [ 1014-25-1 ]
Reference: [1] Journal of Heterocyclic Chemistry, 1984, vol. 21, p. 1689 - 1698
[2] Journal of the Chemical Society, 1957, p. 2858,2860
[3] Journal of the Chemical Society, 1957, p. 2858,2860
[4] Journal of the Chemical Society, 1957, p. 2858,2860
  • 10
  • [ 99-96-7 ]
  • [ 1014-25-1 ]
Reference: [1] Molecular Crystals and Liquid Crystals, 2014, vol. 593, # 1, p. 34 - 42
  • 11
  • [ 3290-99-1 ]
  • [ 1014-25-1 ]
Reference: [1] Arkivoc, 2017, vol. 2017, # 5, p. 293 - 300
  • 12
  • [ 121-98-2 ]
  • [ 1014-25-1 ]
Reference: [1] Arkivoc, 2017, vol. 2017, # 5, p. 293 - 300
  • 13
  • [ 96134-01-9 ]
  • [ 1014-25-1 ]
  • [ 33901-36-9 ]
Reference: [1] Journal of the Chemical Society, 1957, p. 2858,2860
  • 14
  • [ 96134-01-9 ]
  • [ 1014-25-1 ]
  • [ 33901-36-9 ]
Reference: [1] Journal of Heterocyclic Chemistry, 1984, vol. 21, p. 1689 - 1698
  • 15
  • [ 54998-29-7 ]
  • [ 79-19-6 ]
  • [ 1014-25-1 ]
Reference: [1] Festschrift C. Wurster <Ludwigshafen 1960> S. 119, 125,
[2] Patent: DE1067440, 1958, ,
  • 16
  • [ 100-07-2 ]
  • [ 1014-25-1 ]
Reference: [1] Journal of the Chemical Society, 1949, p. 1163,1167[2] Journal of the Chemical Society, 1950, p. 1579,1581
  • 17
  • [ 96134-01-9 ]
  • [ 1014-25-1 ]
  • [ 103989-36-2 ]
Reference: [1] Journal of the Chemical Society, 1957, p. 2858,2860
  • 18
  • [ 123-11-5 ]
  • [ 79-19-6 ]
  • [ 1014-25-1 ]
Reference: [1] European Journal of Medicinal Chemistry, 2015, vol. 95, p. 514 - 525
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 1014-25-1 ]

Aryls

Chemical Structure| 247109-15-5

[ 247109-15-5 ]

5-(3-Methoxyphenyl)-1,3,4-thiadiazol-2-amine

Similarity: 0.99

Chemical Structure| 383130-78-7

[ 383130-78-7 ]

5-(4-Ethylphenyl)-1,3,4-thiadiazol-2-amine

Similarity: 0.82

Chemical Structure| 26907-54-0

[ 26907-54-0 ]

5-(p-Tolyl)-1,3,4-thiadiazol-2-amine

Similarity: 0.82

Chemical Structure| 76074-47-0

[ 76074-47-0 ]

5-(m-tolyl)-1,3,4-Thiadiazol-2-amine

Similarity: 0.82

Chemical Structure| 100987-04-0

[ 100987-04-0 ]

5-(4-(tert-Butyl)phenyl)-1,3,4-thiadiazol-2-amine

Similarity: 0.81

Ethers

Chemical Structure| 247109-15-5

[ 247109-15-5 ]

5-(3-Methoxyphenyl)-1,3,4-thiadiazol-2-amine

Similarity: 0.99

Chemical Structure| 701227-09-0

[ 701227-09-0 ]

2-Methoxy-N-(5-(2-methoxyphenyl)-1,3,4-thiadiazol-2-yl)benzamide

Similarity: 0.69

Chemical Structure| 914348-82-6

[ 914348-82-6 ]

2-(4-Methoxyphenyl)thiazole-5-carbaldehyde

Similarity: 0.52

Chemical Structure| 15884-86-3

[ 15884-86-3 ]

5-(Methoxymethyl)-1,3,4-thiadiazol-2-amine

Similarity: 0.51

Chemical Structure| 101078-51-7

[ 101078-51-7 ]

6-Methoxy-2-(p-tolyl)benzo[d]thiazole

Similarity: 0.50

Amines

Chemical Structure| 247109-15-5

[ 247109-15-5 ]

5-(3-Methoxyphenyl)-1,3,4-thiadiazol-2-amine

Similarity: 0.99

Chemical Structure| 383130-78-7

[ 383130-78-7 ]

5-(4-Ethylphenyl)-1,3,4-thiadiazol-2-amine

Similarity: 0.82

Chemical Structure| 26907-54-0

[ 26907-54-0 ]

5-(p-Tolyl)-1,3,4-thiadiazol-2-amine

Similarity: 0.82

Chemical Structure| 76074-47-0

[ 76074-47-0 ]

5-(m-tolyl)-1,3,4-Thiadiazol-2-amine

Similarity: 0.82

Chemical Structure| 100987-04-0

[ 100987-04-0 ]

5-(4-(tert-Butyl)phenyl)-1,3,4-thiadiazol-2-amine

Similarity: 0.81

Related Parent Nucleus of
[ 1014-25-1 ]

Thiadiazoles

Chemical Structure| 247109-15-5

[ 247109-15-5 ]

5-(3-Methoxyphenyl)-1,3,4-thiadiazol-2-amine

Similarity: 0.99

Chemical Structure| 383130-78-7

[ 383130-78-7 ]

5-(4-Ethylphenyl)-1,3,4-thiadiazol-2-amine

Similarity: 0.82

Chemical Structure| 26907-54-0

[ 26907-54-0 ]

5-(p-Tolyl)-1,3,4-thiadiazol-2-amine

Similarity: 0.82

Chemical Structure| 76074-47-0

[ 76074-47-0 ]

5-(m-tolyl)-1,3,4-Thiadiazol-2-amine

Similarity: 0.82

Chemical Structure| 100987-04-0

[ 100987-04-0 ]

5-(4-(tert-Butyl)phenyl)-1,3,4-thiadiazol-2-amine

Similarity: 0.81